OraLiva, Inc. has been awarded a prestigious Direct to Phase II SBIR grant from the National Institute of Dental and Craniofacial Research (NIDCR) at the National Institutes of Health (NIH). This funding supports the continued development of our groundbreaking AI-linked cytomics-on-a-chip platform.
